# Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

> **NCT03040973** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 29 (actual)

## Conditions studied

- Advanced Solid Tumors Which Are cMET-dependent

## Interventions

- **DRUG:** Capmatinib
- **DRUG:** Nazartinib
- **DRUG:** Gefitinib
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT03040973
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-08-23
- **Primary completion:** 2027-07-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03040973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03040973, "Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03040973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*